服用 GLP-1 受体激动剂减肥药（如 Ozempic 和 Mounjaro）的女性报告了意外怀孕的情况，这引发了人们对胎儿发育的担忧。 Women on GLP-1 receptor agonist weight-loss drugs, like Ozempic and Mounjaro, report unexpected pregnancies, raising concerns for fetal development.
服用 Ozempic 和 Mounjaro 等减肥药（属于 GLP-1 受体激动剂类）的女性报告了意外怀孕的情况，这引发了人们对这些药物可能对胎儿发育产生影响的担忧。 Women taking weight-loss drugs like Ozempic and Mounjaro, part of the GLP-1 receptor agonist class, have reported unexpected pregnancies, raising concerns over their potential impact on fetal development. 这些用于治疗 2 型糖尿病和帮助减肥的药物尚未对孕妇进行研究，并且被排除在临床试验之外。 These medications, used to treat type 2 diabetes and aid weight loss, have not been studied in pregnant individuals and were excluded from clinical trials. 专家建议在尝试怀孕前两个月停止使用这些药物，因为这些药物的制造商诺和诺德和礼来目前正在收集实际使用数据以评估这些药物在怀孕期间的安全性。 Experts recommend stopping these drugs two months before trying to conceive, as their makers, Novo Nordisk and Eli Lilly, are now collecting data from real-world use to assess their safety during pregnancy.